Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline vs Linezolid in ABSSSI (OASIS-1)
NCT02378480Phase 3Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Apr 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of omadacycline in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by Paratek Pharmaceuticals. Primary endpoint: Number of Participants With Early Clinical Response. Started Jun 2015; status: completed.
02
Drugs
omadacycline
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02378480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378480.